These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38753630)

  • 1. The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease.
    Huang L; Bon H; Maamra M; Holmes T; Atkinson J; Cain K; Kennedy J; Kettleborough C; Matthews D; Twomey B; Ni J; Song Z; Watson PF; Johnson TS
    PLoS One; 2024; 19(5):e0298864. PubMed ID: 38753630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.
    Scarpellini A; Huang L; Burhan I; Schroeder N; Funck M; Johnson TS; Verderio EA
    J Am Soc Nephrol; 2014 May; 25(5):1013-27. PubMed ID: 24357671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transglutaminase 2: Development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling.
    Maamra M; Benayad OM; Matthews D; Kettleborough C; Atkinson J; Cain K; Bon H; Brand H; Parkinson M; Watson PF; Johnson TS
    Br J Pharmacol; 2022 Jun; 179(11):2697-2712. PubMed ID: 34879432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic Profiling Reveals the Transglutaminase-2 Externalization Pathway in Kidneys after Unilateral Ureteric Obstruction.
    Furini G; Schroeder N; Huang L; Boocock D; Scarpellini A; Coveney C; Tonoli E; Ramaswamy R; Ball G; Verderio C; Johnson TS; Verderio EAM
    J Am Soc Nephrol; 2018 Mar; 29(3):880-905. PubMed ID: 29382685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration.
    Shweke N; Boulos N; Jouanneau C; Vandermeersch S; Melino G; Dussaule JC; Chatziantoniou C; Ronco P; Boffa JJ
    Am J Pathol; 2008 Sep; 173(3):631-42. PubMed ID: 18688035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
    Wang Z; Perez M; Caja S; Melino G; Johnson TS; Lindfors K; Griffin M
    Cell Death Dis; 2013 Sep; 4(9):e808. PubMed ID: 24052076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between transglutaminases and heparan sulphate in progressive renal scarring.
    Burhan I; Furini G; Lortat-Jacob H; Atobatele AG; Scarpellini A; Schroeder N; Atkinson J; Maamra M; Nutter FH; Watson P; Vinciguerra M; Johnson TS; Verderio EA
    Sci Rep; 2016 Oct; 6():31343. PubMed ID: 27694984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feline chronic kidney disease is associated with upregulation of transglutaminase 2: a collagen cross-linking enzyme.
    Sánchez-Lara AC; Elliott J; Syme HM; Brown CA; Haylor JL
    Vet Pathol; 2015 May; 52(3):513-23. PubMed ID: 25047228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor.
    Wang Z; Stuckey DJ; Murdoch CE; Camelliti P; Lip GYH; Griffin M
    Cell Death Dis; 2018 Apr; 9(6):613. PubMed ID: 29795262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isozyme-specific comprehensive characterization of transglutaminase-crosslinked substrates in kidney fibrosis.
    Tatsukawa H; Otsu R; Tani Y; Wakita R; Hitomi K
    Sci Rep; 2018 May; 8(1):7306. PubMed ID: 29743665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the heparan sulphate-dependent externalisation of transglutaminase-2 (TG2) in glucose-stimulated proximal-like tubular epithelial cells.
    Furini G; Burhan I; Huang L; Savoca MP; Atobatele A; Johnson T; Verderio EAM
    Anal Biochem; 2020 Aug; 603():113628. PubMed ID: 32074489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
    Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
    Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition.
    Prat-Duran J; Pinilla E; Nørregaard R; Simonsen U; Buus NH
    Pharmacol Ther; 2021 Jun; 222():107787. PubMed ID: 33307141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a unilateral ureteral obstruction model in cynomolgus monkeys.
    Huang L; Ni J; Duncan T; Song Z; Johnson TS
    Animal Model Exp Med; 2021 Dec; 4(4):359-368. PubMed ID: 34977487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).
    Valdivia A; Vagadia PP; Guo G; O'Brien E; Matei D; Schiltz GE
    J Med Chem; 2023 Jul; 66(14):9445-9465. PubMed ID: 37449845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary levels of pro-fibrotic transglutaminase 2 (TG2) may help predict progression of chronic kidney disease.
    Da Silva Lodge M; Pullen N; Pereira M; Johnson TS
    PLoS One; 2022; 17(1):e0262104. PubMed ID: 35041708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice.
    Popov Y; Sverdlov DY; Sharma AK; Bhaskar KR; Li S; Freitag TL; Lee J; Dieterich W; Melino G; Schuppan D
    Gastroenterology; 2011 May; 140(5):1642-52. PubMed ID: 21277850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies.
    Caja S; Myrsky E; Korponay-Szabo IR; Nadalutti C; Sulic AM; Lavric M; Sblattero D; Marzari R; Collighan R; Mongeot A; Griffin M; Mäki M; Kaukinen K; Lindfors K
    Scand J Gastroenterol; 2010 Apr; 45(4):421-7. PubMed ID: 20095873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung-specific interleukin 6 mediated transglutaminase 2 activation and cardiopulmonary fibrogenesis.
    Penumatsa KC; Sharma Y; Warburton RR; Singhal A; Toksoz D; Bhedi CD; Qi G; Preston IR; Anderlind C; Hill NS; Fanburg BL
    Front Immunol; 2024; 15():1371706. PubMed ID: 38650935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.